Wound Management Technologies (OTCMKTS:WNDM) and Precision Therapeutics (NASDAQ:POAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.
This table compares Wound Management Technologies and Precision Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wound Management Technologies||-10.28%||-39.28%||-21.49%|
This is a breakdown of current ratings and recommmendations for Wound Management Technologies and Precision Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wound Management Technologies||0||0||0||0||N/A|
Insider and Institutional Ownership
1.1% of Precision Therapeutics shares are owned by institutional investors. 75.4% of Wound Management Technologies shares are owned by company insiders. Comparatively, 13.4% of Precision Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Wound Management Technologies and Precision Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Wound Management Technologies||$5.84 million||1.83||-$600,000.00||N/A||N/A|
|Precision Therapeutics||$1.41 million||12.84||-$10.09 million||N/A||N/A|
Wound Management Technologies has higher revenue and earnings than Precision Therapeutics.
Volatility and Risk
Wound Management Technologies has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Precision Therapeutics has a beta of 2.42, indicating that its share price is 142% more volatile than the S&P 500.
Wound Management Technologies beats Precision Therapeutics on 6 of the 9 factors compared between the two stocks.
Wound Management Technologies Company Profile
WNDM Medical Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. The company offers HemaQuell, a resorbable bone hemostat for bone healing; and CellerateRX surgical for healing. The company was formerly known as Wound Management Technologies, Inc. and changed its name to WNDM Medical Inc. in April 2017. WNDM Medical Inc. was founded in 1982 and is based in Fort Worth, Texas.
Precision Therapeutics Company Profile
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.
Receive News & Ratings for Wound Management Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wound Management Technologies and related companies with MarketBeat.com's FREE daily email newsletter.